It is worth mentioning here that despite promising therapeutic results, similar to many targeted cancer therapies, different types of PI3K inhibitors (pan-/isoform-specific) may give rise to serious adverse effects that restrict their clinical applications [31]. The gene discussed is PIK3CD; the disease is cancer.